Incretin based therapy and pancreatic cancer:Realising the reality  

作　　者：Varun Suryadevara Ayan Roy Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik Pazhanivel Mohan Raja Kalayarasan 

机构地区：[1]Department of Endocrinology,Jawaharlal Institute of Postgraduate Medical Education and Research,Puducherry 605006,India [2]Department of Endocrinology,All India Institute of Medical Sciences,Kalyani 741245,West Bengal,India [3]Department of Medical Gastroenterology,Jawaharlal Institute of Postgraduate Medical Education and Research,Puducherry 605006,India [4]Department of Surgical Gastroenterology,Jawaharlal Institute of Postgraduate Medical Education and Research,Puducherry 605006,India

出　　处：《World Journal of Gastroenterology》2022年第25期2881-2889,共9页世界胃肠病学杂志（英文版）

摘　　要：Incretin-based therapies like glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help maintain the glycaemic control in patients with type 2 diabetes mellitus with additional systemic benefits and little risk of hypoglycaemia.These medications are associated with low-grade chronic pancreatitis in animal models inconsistently.The incidence of acute pancreatitis was also reported in some human studies.This inflammation provides fertile ground for developing pancreatic carcinoma(PC).Although the data from clinical trials and population-based studies have established safety regarding PC,the pathophysiological possibility that low-grade chronic pancreatitis leads to PC remains.We review the existing literature and describe the relationship between incretin-based therapies and PC.

关 键 词：Diabetes mellitus Dipeptidyl peptidase-4 inhibitor Glucagon-like peptide-1 receptor agonist INCRETIN PANCREATITIS Pancreatic Cancer 

分 类 号：R735.9[医药卫生—肿瘤]